Stereoselective Access to Antimelanoma Agents by Hybridization and Dimerization of Dihydroartemisinin and Artesunic acid. 2021

Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
Department of Biological and Ecological Sciences, Univeristy of Viterbo, Via S.C. De Lellis s.n.c., 01100, Viterbo, Italy.

A library of five hybrids and six dimers of dihydroartemisinin and artesunic acid has been synthetized in a stereo-controlled manner and evaluated for the anticancer activity against metastatic melanoma cell line (RPMI7951). Among novel derivatives, three artesunic acid dimers showed antimelanoma activity and cancer selectivity, being not toxic on normal human fibroblast (C3PV) cell line. Among the three dimers, the one bearing 4-hydroxybenzyl alcohol as a spacer showed no cytotoxic effect (CC50 >300 μM) and high antimelanoma activity (IC50 =0.05 μM), which was two orders of magnitude higher than that of parent artesunic acid, and of the same order of commercial drug paclitaxel. In addition, this dimer showed cancer-type selectivity towards melanoma compared to prostate (PC3) and breast (MDA-MB-231) tumors. The occurrence of a radical mechanism was hypothesized by DFO and EPR analyses. Qualitative structure activity relationships highlighted the role of artesunic acid scaffold in the control of toxicity and antimelanoma activity.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013386 Succinates Derivatives of SUCCINIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a 1,4-carboxy terminated aliphatic structure. Succinic Acids,Acids, Succinic

Related Publications

Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
February 1998, The Journal of pharmacy and pharmacology,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
April 2019, ChemMedChem,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
April 1997, Journal of chromatography. B, Biomedical sciences and applications,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
September 2012, Bioorganic & medicinal chemistry,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
April 2005, Chembiochem : a European journal of chemical biology,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
September 2022, International journal of molecular sciences,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
November 2020, The Journal of organic chemistry,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
September 2008, Organic letters,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
October 2003, The Journal of biological chemistry,
Lorenzo Botta, and Silvia Cesarini, and Claudio Zippilli, and Silvia Filippi, and Bruno Mattia Bizzarri, and Maria Camilla Baratto, and Rebecca Pogni, and Raffaele Saladino
November 2010, Chemical communications (Cambridge, England),
Copied contents to your clipboard!